Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TPH1 | P17752 | 1/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL28430992 | 1.00 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL180587 | 1.00 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27531942 | 0.93 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL7764501 | 0.93 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL7764495 | 0.93 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1724134 | 0.92 | SLC7A5 (0.60) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27625516 | 0.92 | SLC7A5 (0.60) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28477318 | 0.91 | SLC7A5 (0.58) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8630269 | 0.91 | SLC7A5 (0.58) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1585313 | 0.91 | SLC7A5 (0.58) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-11-12 | — | — | US | claimed |
| EP-3707157-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2020-09-16 | — | — | EP | claimed |
| CN-111479823-A | Peptide conjugate CGRP receptor antagonist and preparation method and application thereof | 奥克兰联合服务有限公司 | 2020-07-31 | — | — | CN | claimed |
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-11-12 | — | — | US | disclosed |
| EP-3707157-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2020-09-16 | — | — | EP | disclosed |
| CN-111479823-A | Peptide conjugate CGRP receptor antagonist and preparation method and application thereof | 奥克兰联合服务有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-110234346-A | Novel vaccine against Zika virus and combination of DNA antibody constructs for use against Zika virus | 宾夕法尼亚大学理事会 | 2019-09-13 | — | — | CN | disclosed |
| WO-2019078697-A2 | ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME | 주식회사 녹십자 | 2019-04-25 | — | — | WO | disclosed |
| US-20150111816-A1 | METHODS AND TREATMENT WITH GLP-1 RECEPTOR AGONISTS | PHASEBIO PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140364362-A1 | THERAPEUTIC AGENTS COMPRISING INSULIN AMINO ACID SEQUENCES | PHASEBIO PHARMACEUTICALS INC (US) | 2014-12-11 | — | — | US | disclosed |
| EP-2400974-A2 | SYNTHETIC DIBLOCK COPOLYPEPTIDE HYDROGELS FOR USE IN THE CENTRAL NERVOUS SYSTEM | The Regents Of The University Of California (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010096572-A2 | SYNTHETIC DIBLOCK COPOLYPEPTIDE HYDROGELS FOR USE IN THE CENTRAL NERVOUS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-26 | — | — | WO | disclosed |
| EP-1750521-A1 | METHOD AND SYSTEM FOR SOLUBILIZING PROTEIN | The Texas A&M University System (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117602-A1 | METHOD AND SYSTEM FOR SOLUBILIZING PROTEIN | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-12-15 | — | — | WO | disclosed |
| US-5062935-A | METHOD OF VAPORIZING A SAMPLE SUBSTANCE | BRUKER-FRANZEN ANALYTIK GMBH (DE) | 1991-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | CALCRL, CALCR, GRPR | SLC7A5 1069/4885PTGS1 1469/4885ALPI 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.